← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Patel Snehal
Chief Executive Officer | Chief Financial Officer
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001806920
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 11
- Purchases · 24M
- 21
- Average purchase
- $45.4K
- Median purchase
- $39.4K
- Gross purchase value
- $952.6K
Companies: Greenwich LifeSciences, Inc.
21 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-07-30 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $29.6K | Open filing |
| 2026-07-29 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $20.4K | Open filing |
| 2026-07-27 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $47.0K | Open filing |
| 2026-01-15 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $53.7K | Open filing |
| 2026-01-14 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $79.9K | Open filing |
| 2026-01-05 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $91.8K | Open filing |
| 2026-01-02 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $63.0K | Open filing |
| 2025-12-19 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $51.7K | Open filing |
| 2025-11-28 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $38.5K | Open filing |
| 2025-11-12 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $89.4K | Open filing |
| 2025-11-04 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $21.3K | Open filing |
| 2025-04-29 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $35.6K | Open filing |
| 2025-04-22 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $48.5K | Open filing |
| 2025-04-08 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $32.8K | Open filing |
| 2025-04-07 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $48.0K | Open filing |
| 2025-01-13 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $31.3K | Open filing |
| 2025-01-08 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $39.4K | Open filing |
| 2025-01-07 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $44.0K | Open filing |
| 2025-01-06 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $23.9K | Open filing |
| 2025-01-03 | Greenwich LifeSciences, Inc. | GLSI | Chief Executive Officer | Chief Financial Officer | $27.3K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
No completed point-in-time price outcome is available yet.
Research patterns
- First purchase in 12M
- 0/20
- Large purchase ≥ $100k
- 0/21
- Cluster buying · 15D
- 0/21
- Buying the dip
- 0/—
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.